GlobeNewswire·Nov 11, 2026, 4:32 PM ET

Addex Spin-out Neurosterix Closes $105 Million Series B Financing

Addex Therapeutics announced that its spin-out company, Neurosterix, closed a $105 million Series B financing from a syndicate of life science investors.
Addex did not participate in the financing & now holds an 8.5% equity interest in Neurosterix valued at $18.6 million.
Proceeds will primarily support the Phase 2 clinical development of NTX-253, a selective muscarinic M4 positive allosteric modulator for schizophrenia.
Funding will also support Neurosterix's broader pipeline of allosteric modulators targeting neuropsychiatric disorders.
NTX-253 has completed Phase 1 studies & aims to fine-tune brain signaling to reduce psychosis symptoms while avoiding movement disorders & metabolic complications.
Neurosterix's pipeline includes NTX-253 for schizophrenia, NTX-819 for mood & anxiety disorders, & NTX-529 for psychosis & mood-related disorders.
Addex maintains a separate portfolio including dipraglurant for brain injury recovery, a GABAB PAM candidate for substance use disorders, & a differentiated GABAB PAM for chronic cough.